Veeda Clinical Research Ltd.

DUBLIN and AHMEDABAD, India, March 26, 2024 /PRNewswire/ -- Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has an operational presence in 25 multiple strategically important locations across Europe, North America and the Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch. Sharing details related to common synergies between Veeda and Heads, Dr. Mahesh Bhalgat, Group – CEO of Veeda Clinical Research, said, "With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies." Elaborating on the prospects of this partnership, Mr. Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, "As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide." "There is a very strong cultural fit between Heads and Veeda," said Dr. George Kouvatseas, Partner, Heads. "Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, and an uncompromising focus on quality. During the integration phase, Heads will continue to offer uninterrupted support to client programs. The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programs." About Veeda Clinical Research Limited: Veeda Clinical Research Limited ("Veeda") is one of the largest independent, full-service clinical research organizations, headquartered in Ahmedabad, India. Veeda offers a range of bioequivalence studies and early and late phase clinical trials. Veeda has successfully completed several regulatory inspections and is approved by USFDA, UK MHRA, ANVISA (Brazil), and WHO. Veeda has experience in conducting complex clinical studies. Visit . About Heads: Heads is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in haemato-oncology studies. It provides complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, it offers strategic oncology drug development consulting and expert advice, as the team understands the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market. Visit . Media contact: Siddharth Baad Corporate Communications Veeda Clinical Research siddharth.b2274@veedacr.com Logo: View original content to download multimedia: SOURCE Veeda Clinical Research Limited

DUBLIN, Dec. 14, 2022 /PRNewswire/ -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of individual therapies. In addition to other elements, the study includes a detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and other development activities. Report Highlights: Global Anti-TIGIT Antibodies Market Dynamics Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication Anti-TIGIT Antibodies In Clinical Trials : > 45 Overview Of Partnerships and Collaborations In The Global Anti-TIGIT Antibodies Market Global Anti-TIGIT Antibodies Market Outlook Competitive Landscape The advancement in the field of genomics has led to the identification of T-cell immunoreceptors with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed in multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is upregulated in T cells and NK cells after ligand binding, inhibiting these cells' ability to kill tumor cells. Increased TIGIT expression s also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence. Since its identification as a potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mice. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the Fcandgamma; R, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further been shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells. Recent years have seen an increase in collaborations and partnerships between companies for the faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former's potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug's Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug's safety, pharmacokinetic properties, and tolerability post-dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors. Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests a promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of the majority of regions is shifting towards novel therapeutic approaches drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. As per report findings, the global market is expected to have opportunity of more than US$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti-TIGIT Antibody clinical development and the market opportunity are driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among the population, and the development of favorable reimbursement policies are also boosting the growth of the market during the forecast period. Key Topics Covered: 1. Introduction to TIGIT Inhibitor 2. Role Of TIGIT Inhibitors By Indications 2.1 TIGIT Inhibitors in Cancer 2.2 TIGIT Inhibitors in HIV 2.3 TIGIT in Autoimmune Disorders 3. Mechanism of Anti TIGIT Antibodies 3.1 Overview 3.2 Clinical Approaches to Target TIGIT 4. Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market 5. Global TIGIT inhibitors Clinical Trials Overview 5.1 By Company 5.2 By Country 5.3 By Indication 5.4 By Patient Segment 6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication and Phase 6.1 Research 6.2 Preclinical 6.3 Phase-I 6.4 Phase-I/II 6.5 Phase-II 6.6 Phase-III 7. FDA Orphan Designation for Tiragolumab 8. Global Anti TIGIT Antibody Market Dynamics 8. 1 Market Drivers 8.2 Commercialization Challenges 9. Global TIGIT Inhibitor Market Future Outlook 10. Competitive Landscape 10.1 Arcus Biosciences 10.2 Agenus 10.3 Astellas Pharma 10.4 AstraZeneca 10.5 BeiGene 10.6 Bristol Myers Squibb 10.7 Compugen 10.8 Gilead Sciences 10.9 iTeos Therapeutics 10.10 Merck 10.11 Roche 10.12 Seagen 10.13 Shanghai Henlius Biotech For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

JERSEY CITY, N.J., Nov. 22, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Clinical Trial Planning and Design Services Market By (Trial Phases (Phase I, Phase II, Phase III, and Phase IV), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, And Other Therapeutic Areas), Services (Statistical Analysis Plan, Ecrf, Site Identification And Selection, Medical Writing, And Other Services)) -Trends, Industry Competition Analysis, Revenue, and Forecast To 2030." According to the latest research by InsightAce Analytic, the global clinical trial planning and design services market size is expected to grow at a CAGR of 8.27% during the forecast period (2022-2030). Clinical trial services are opted for by pharmaceutical companies during the trial of their new drug molecule or molecular analysis of biosimilars before introducing a new drug launch to the market. The rising number of clinical trials, expiry of blockbuster drugs, increasing number of CROs, increasing R&D expenditure in pharmaceutical and biopharmaceutical companies, and rising prevalence of chronic diseases are some of the key factors driving this market. However, the high cost of devices with advanced technologies, stringent government regulations for enrollment of patients, and poor reimbursement policies are expected to downscale the market growth during the forecast period 2022-2030. Request for Sample Pages: The phase III segment is estimated to dominate the market in 2020 due to the requirement of many participants and high expenses. Advanced planning and designing techniques for clinical trials are increasingly used in various clinical trials. The clinical trial services provide helpful information to the trial conducting pharmaceutical and biotechnology companies. For instance, in July 2021, CD BioSciences, a provider of comprehensive clinical trial services, introduced Randomization Plan Design services for various clinical trials to the scientific and research communities. The newly launched service is expected to help the users to develop a clear and simple randomization plan to ensure its unpredictability and balance and thus reduce or eliminate bias. The oncological disorders segment is estimated to be the fastest-growing therapeutic segment of the clinical trial planning and design services market due to the increasing prevalence of cancer, which leads to growth in novel clinical trial imaging techniques. Geographically, North America is estimated to dominate the clinical trial planning and design services market in 2021. The segment is expected to have the same growth trend over the forecast period owing to the increasing number of pharmaceutical companies and subsequent increase in their R&D expenditure, increasing prevalence of diseases, and favorable government for clinical trials and research. However, the Asia-Pacific region is expected to be the fastest-growing region due to the rising healthcare expenditure and high demand for clinical trials during the study period. Some of the key players operating in the clinical trial planning and design services market are Atlantia Clinical Trials, PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences, LLX Solutions, SGS, ADM Korea, McDougall Scientific, ClinAsia, BioPoint, IQVIA, PPD, Inc., Veristat, LLC, Clinical Accelerator, Allied Clinical Management GmbH, Parexel International Corporation, Pepgra, WIRB-Copernicus Group, Afortiori Development Ltd, Celerion, CCS (Cardiovascular Clinical Sciences), MCRA, dicentra, DOT WORLD (Japan) and other. Curious about this latest version of the report? Obtain Report Details @ The market players are focusing on the strategies such as the launch of novel techniques, partnerships, collaborations, and acquisitions to retain their market position. For instance, In Sept 2022, Cytel Inc.'s business extended across the Asia-Pacific area (APAC). This enables Cytel's existing biometrics and advanced statistical solutions to be more accessible to APAC biotech and biopharma enterprises. Cytel now has operations in Australia, Shanghai, Beijing, and Singapore, with plans to grow into Seoul and Tokyo in the future. This expansion is the latest move in Cytel's goal to provide advanced analytics capabilities to drug developers worldwide. In Sept 2022, Parexel announced the opening of a new clinical trial supplies and logistics facility in Suzhou, China. This strategically positioned facility offers local and international biopharmaceutical companies conducting clinical trials in the region quick access to supplies and investigational therapies to distribute to clinical locations and patients worldwide. In March 2022, Emergo by UL created the Optimal Product Usability SuiteTM, a web-based platform (OPUS). This software as a service (SaaS) product provides medical device and technology firms convenient access to human factors engineering (HFE) skills to help with regulatory and commercial initiatives. In March 2021, Cytel Inc. launched East® Bayes, an enhanced web-based extension of the East® platform that enables the adoption of the most computationally intensive Bayesian clinical trial designs – without the need for powerful on-site computers. The newly launched web-based extension further expands East's arsenal of Bayesian trial designs by providing a suite of complex phase I dose-escalation and phase II dose-finding designs for greater speed, flexibility, and cost-effectiveness in early clinical development. In March 2021, CD BioScences announced that it would offer global early-phase clinical services to researchers. The company claims to advise worldwide scientists through the obstacles of clinical trial development, particularly in reducing time spent in early-phase clinical trials, lowering costs, and lowering potential dangers. In Jan 2020, Veristat has expanded its European reach with the acquisition of The Clinical Trial Company (TCTC Group), another CRO. Veristat will obtain ownership of TCTC Group's experience in project management and clinical operations across Europe due to the transaction. Market Segments Clinical Trial Planning And Design Services Market Revenue, by Trial Phases, 2019-2030 (Value US$ Mn) Phase I Phase II Phase III Phase IV Clinical Trial Planning And Design Services Market Revenue, by Therapeutic Area, 2019-2030 (Value US$ Mn) Oncological Disorders Cardiovascular Disorders Inflammatory Disorders Neurological Disorders Other Therapeutic Areas Clinical Trial Planning And Design Services Market Revenue, by Services, 2019-2030 (Value US$ Mn) Statistical Analysis Plan eCRF Site Identification and Selection Medical Writing Other Services Clinical Trial Planning And Design Services Market Revenue by Region, 2019-2030 (Value US$ Mn) North America Europe Asia Pacific Latin America Middle East & Africa North America Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) U.S. Canada Europe Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) Germany France Italy Spain Russia Rest of Europe Asia Pacific Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) India China Japan South Korea Australia & New Zealand Latin America Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) Brazil Mexico Rest of Latin America Middle East & Africa Clinical Trial Planning And Design Services Market Revenue by Country, 2019-2030 (Value US$ Mn) GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for the global clinical trial planning and design services market To receive industry overview and future trends in clinical trial planning and design services market To analyze the global clinical trial planning and design services market drivers and challenges To get information on clinical trial planning and design services market size (US$ Mn) and forecast to 2030 To analyze the significant developments such as investments, mergers & acquisition in clinical trial planning and design services market industry For More Information @ Other Related Reports Published by InsightAce Analytic: Global Clinical Trials Software Market Global AI-Based Clinical Trial Solution Providers Market Global Site Management Organizations (SMO) Market Global Patient Recruitment and Retention Services Market Global Clinical Trial Imaging Services Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ Logo: SOURCE InsightAce Analytic Pvt. Ltd